How does TCR-T cell therapy exhibit a superior anti-tumor efficacy

Area of Science:

• Oncology
• Immunotherapy
• Cell Therapy

Background:

• T-cell receptor (TCR)-engineered T cell therapy has advanced significantly in treating solid tumors, with some approaches entering clinical trials.
• Understanding the current landscape of TCR-T cell therapy is crucial for guiding future research and clinical applications.

Purpose of the Study:

• To review the progress of TCR-T cell therapy in solid tumor treatment.
• To classify tumor antigens and analyze TCR-T cell therapy targeting these antigens.
• To explore strategies for enhancing TCR-T cell therapy efficacy.

Main Methods:

• Classification of tumor antigens into four categories: tumor-associated, tumor-specific, oncogenic virus-expressed, and abnormal protein modification-related.
• Detailed review of TCR-T cell therapy effects in clinical and preclinical trials targeting these antigens.
• Summary of optimization strategies for improving TCR-T cell therapy.

Main Results:

• Neoantigen-specific TCR-T cell therapy is identified as a highly promising approach for solid tumors.
• Various TCR-T cell therapies targeting different antigen types have shown efficacy in trials.
• Optimization strategies including modulating the tumor microenvironment and enhancing TCR pairing and affinity are crucial for therapeutic success.

Conclusions:

• TCR-T cell therapy represents a significant advancement in solid tumor treatment.
• Targeting neoantigens with TCR-engineered T cells holds substantial potential for future cancer therapies.
• Further research into antigen selection and therapeutic optimization is essential for maximizing the impact of TCR-T cell therapy.